메뉴 건너뛰기




Volumn 2015, Issue , 2015, Pages

Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: A randomized controlled trial

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; PLACEBO; SULODEXIDE; TRANSFORMING GROWTH FACTOR BETA1; ALBUMINOID; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSAMINOGLYCAN; TGFB1 PROTEIN, HUMAN;

EID: 84928494344     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/172038     Document Type: Article
Times cited : (15)

References (31)
  • 2
    • 84869492851 scopus 로고    scopus 로고
    • Cardiorenal end points in a trial of aliskiren for type 2 diabetes
    • H.-H. Parving, B. M. Brenner, J. J. V. McMurray et al., "Cardiorenal end points in a trial of aliskiren for type 2 diabetes," The New England Journal ofMedicine, vol. 367, no. 23, pp. 2204-2213, 2012.
    • (2012) The New England Journal OfMedicine , vol.367 , Issue.23 , pp. 2204-2213
    • Parving, H.-H.1    Brenner, B.M.2    McMurray, J.J.V.3
  • 3
    • 84890946148 scopus 로고    scopus 로고
    • Bardoxolonemethyl in type 2 diabetes and stage 4 chronic kidney disease
    • D. de Zeeuw, T. Akizawa, P. Audhya et al., "Bardoxolonemethyl in type 2 diabetes and stage 4 chronic kidney disease," The New England Journal of Medicine, vol. 369, no. 26, pp. 2492-2503, 2013.
    • (2013) The New England Journal of Medicine , vol.369 , Issue.26 , pp. 2492-2503
    • De Zeeuw, D.1    Akizawa, T.2    Audhya, P.3
  • 4
    • 10744223527 scopus 로고    scopus 로고
    • Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
    • W. K. Bolton, D. C. Cattran, M. E. Williams et al., "Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy," The American Journal of Nephrology, vol. 24, no. 1, pp. 32-40, 2004.
    • (2004) The American Journal of Nephrology , vol.24 , Issue.1 , pp. 32-40
    • Bolton, W.K.1    Cattran, D.C.2    Williams, M.E.3
  • 5
    • 79957467422 scopus 로고    scopus 로고
    • Review on pathophysiology and treatment of diabetic kidney disease
    • B. Satirapoj, "Review on pathophysiology and treatment of diabetic kidney disease," Journal of the Medical Association of Thailand, vol. 93, supplement 6, pp. S228-S241, 2010.
    • (2010) Journal of the Medical Association of Thailand , vol.93 , pp. S228-S241
    • Satirapoj, B.1
  • 7
    • 0029355274 scopus 로고
    • Fibrosis linked to TGF-beta in yet another disease
    • W. A. Border and N. A. Noble, "Fibrosis linked to TGF-beta in yet another disease,"The Journal of Clinical Investigation, vol. 96, no. 2, pp. 655-656, 1995.
    • (1995) The Journal of Clinical Investigation , vol.96 , Issue.2 , pp. 655-656
    • Border, W.A.1    Noble, N.A.2
  • 8
    • 0025277164 scopus 로고
    • Suppression of experimental glomerulonephritis by antiserum against transforming growth factor 1
    • W. A. Border, S. Okuda, L. R. Languino, M. B. Sporn, and E. Ruoslahti, "Suppression of experimental glomerulonephritis by antiserum against transforming growth factor 1," Nature, vol. 346, no. 6282, pp. 371-374, 1990.
    • (1990) Nature , vol.346 , Issue.6282 , pp. 371-374
    • Border, W.A.1    Okuda, S.2    Languino, L.R.3    Sporn, M.B.4    Ruoslahti, E.5
  • 9
    • 0029905441 scopus 로고    scopus 로고
    • Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
    • Y. Isaka, D. K. Brees, K. Ikegaya et al., "Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney," Nature Medicine, vol. 2, no. 4, pp. 418-423, 1996.
    • (1996) Nature Medicine , vol.2 , Issue.4 , pp. 418-423
    • Isaka, Y.1    Brees, D.K.2    Ikegaya, K.3
  • 10
    • 0029924637 scopus 로고    scopus 로고
    • Neutralization of TGF-by anti-TGF-antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZinduced diabetic mice
    • K. Sharma, Y. Jin, J. Guo, and F. N. Ziyadeh, "Neutralization of TGF-by anti-TGF-antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZinduced diabetic mice," Diabetes, vol. 45, no. 4, pp. 522-530, 1996.
    • (1996) Diabetes , vol.45 , Issue.4 , pp. 522-530
    • Sharma, K.1    Jin, Y.2    Guo, J.3    Ziyadeh, F.N.4
  • 11
    • 0036014944 scopus 로고    scopus 로고
    • Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di. N. A. S. Randomized trial
    • G. Gambaro, I. Kinalska, A. Oksa et al., "Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di. N. A. S. randomized trial," Journal of theAmerican Society of Nephrology, vol. 13, no. 6, pp. 1615-1625, 2002.
    • (2002) Journal of TheAmerican Society of Nephrology , vol.13 , Issue.6 , pp. 1615-1625
    • Gambaro, G.1    Kinalska, I.2    Oksa, A.3
  • 12
    • 0030071492 scopus 로고    scopus 로고
    • Effect of suiphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy
    • J. T. Tamsma, F. J. vanderWoude, andH. H. P. J. Lemkes, "Effect of suiphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy," Nephrology Dialysis Transplantation, vol. 11, no. 1, pp. 182-185, 1996.
    • (1996) Nephrology Dialysis Transplantation , vol.11 , Issue.1 , pp. 182-185
    • Tamsma, J.T.1    Vanderwoude, F.J.2    Lemkes, H.H.P.J.3
  • 13
    • 0028092966 scopus 로고
    • Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy
    • G. Gambaro, A. P. Venturini, D. M. Noonan et al., "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy," Kidney International, vol. 46, no. 3, pp. 797-806, 1994.
    • (1994) Kidney International , vol.46 , Issue.3 , pp. 797-806
    • Gambaro, G.1    Venturini, A.P.2    Noonan, D.M.3
  • 14
    • 0026659040 scopus 로고
    • Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats
    • G. Gambaro, A. O. Cavazzana, P. Luzi et al., "Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats," Kidney International, vol. 42, no. 2, pp. 285-291, 1992.
    • (1992) Kidney International , vol.42 , Issue.2 , pp. 285-291
    • Gambaro, G.1    Cavazzana, A.O.2    Luzi, P.3
  • 15
    • 0033672331 scopus 로고    scopus 로고
    • Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-termdiabetic rats
    • M. Ceol, G. Gambaro, U. Sauer et al., "Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-termdiabetic rats," Journal of the American Society of Nephrology, vol. 11, no. 12, pp. 2324-2336, 2000.
    • (2000) Journal of the American Society of Nephrology , vol.11 , Issue.12 , pp. 2324-2336
    • Ceol, M.1    Gambaro, G.2    Sauer, U.3
  • 16
    • 84903135790 scopus 로고    scopus 로고
    • Heparanase is a key player in renal fibrosis by regulating TGF-expression and activity
    • V. Masola, G. Zaza, M. F. Secchi, G. Gambaro, A. Lupo, and M. Onisto, "Heparanase is a key player in renal fibrosis by regulating TGF-expression and activity," Biochimica et Biophysica Acta, vol. 1843, no. 9, pp. 2122-2128, 2014.
    • (2014) Biochimica et Biophysica Acta , vol.1843 , Issue.9 , pp. 2122-2128
    • Masola, V.1    Zaza, G.2    Secchi, M.F.3    Gambaro, G.4    Lupo, A.5    Onisto, M.6
  • 17
    • 0033661906 scopus 로고    scopus 로고
    • Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c
    • C. Ito, R. Maeda, S. Ishida, H. Sasaki, and H. Harada, "Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c," Diabetes Research and Clinical Practice, vol. 50, no. 3, pp. 225-230, 2000.
    • (2000) Diabetes Research and Clinical Practice , vol.50 , Issue.3 , pp. 225-230
    • Ito, C.1    Maeda, R.2    Ishida, S.3    Sasaki, H.4    Harada, H.5
  • 18
    • 33847202536 scopus 로고    scopus 로고
    • Improvement of renal function in type 2 diabetic nephropathy
    • N. Futrakul, P. Butthep, P. Futrakul, and V. Sitprija, "Improvement of renal function in type 2 diabetic nephropathy," Renal Failure, vol. 29, no. 2, pp. 155-158, 2007.
    • (2007) Renal Failure , vol.29 , Issue.2 , pp. 155-158
    • Futrakul, N.1    Butthep, P.2    Futrakul, P.3    Sitprija, V.4
  • 20
    • 84858765166 scopus 로고    scopus 로고
    • Novel insights into the relationship between glomerular pathology and progressive kidney disease
    • B. Satirapoj, C. C. Nast, and S. G. Adler, "Novel insights into the relationship between glomerular pathology and progressive kidney disease," Advances in Chronic Kidney Disease, vol. 19, no. 2, pp. 93-100, 2012.
    • (2012) Advances in Chronic Kidney Disease , vol.19 , Issue.2 , pp. 93-100
    • Satirapoj, B.1    Nast, C.C.2    Adler, S.G.3
  • 21
    • 0029060919 scopus 로고
    • Overexpression of transforming growth factor-1 mRNA is associated with upregulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice
    • C.-W. Yang, M. Hattori, H. Vlassara et al., "Overexpression of transforming growth factor-1 mRNA is associated with upregulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice," Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1610-1617, 1995.
    • (1995) Journal of the American Society of Nephrology , vol.5 , Issue.8 , pp. 1610-1617
    • Yang, C.-W.1    Hattori, M.2    Vlassara, H.3
  • 22
    • 0031053824 scopus 로고    scopus 로고
    • Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes
    • I. S. Park, H. Kiyomoto, S. L. Abboud, and H. E. Abboud, "Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes," Diabetes, vol. 46, no. 3, pp. 473-480, 1997.
    • (1997) Diabetes , vol.46 , Issue.3 , pp. 473-480
    • Park, I.S.1    Kiyomoto, H.2    Abboud, S.L.3    Abboud, H.E.4
  • 23
    • 0029924863 scopus 로고    scopus 로고
    • High glucose-induced TGF-1 regulates mesangial production of heparan sulfate proteoglycan
    • V. Kolm, U. Sauer, B. Olgemöller, and E. D. Schleicher, "High glucose-induced TGF-1 regulates mesangial production of heparan sulfate proteoglycan," The American Journal of Physiology, vol. 270, no. 5, part 2, pp. F812-F821, 1996.
    • (1996) The American Journal of Physiology , vol.270 , Issue.5 , pp. F812-F821
    • Kolm, V.1    Sauer, U.2    Olgemöller, B.3    Schleicher, E.D.4
  • 24
    • 0030957881 scopus 로고    scopus 로고
    • Glycosaminoglycans delay the progression of nephropathy in NIDDM
    • A. Solini, L. Vergnani, F. Ricci, and G. Crepaldi, "Glycosaminoglycans delay the progression of nephropathy in NIDDM," Diabetes Care, vol. 20, no. 5, pp. 819-823, 1997.
    • (1997) Diabetes Care , vol.20 , Issue.5 , pp. 819-823
    • Solini, A.1    Vergnani, L.2    Ricci, F.3    Crepaldi, G.4
  • 26
    • 77955440687 scopus 로고    scopus 로고
    • Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy
    • S. Blouza, S. Dakhli, H. Abid et al., "Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy," Journal of Nephrology, vol. 23, no. 4, pp. 415-424, 2010.
    • (2010) Journal of Nephrology , vol.23 , Issue.4 , pp. 415-424
    • Blouza, S.1    Dakhli, S.2    Abid, H.3
  • 27
    • 33846443180 scopus 로고    scopus 로고
    • Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients
    • B. Sulikowska, H. Olejniczak, M. Muszýnska et al., "Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients," American Journal of Nephrology, vol. 26, no. 6, pp. 621-628, 2006.
    • (2006) American Journal of Nephrology , vol.26 , Issue.6 , pp. 621-628
    • Sulikowska, B.1    Olejniczak, H.2    Muszýnska, M.3
  • 28
    • 80055018022 scopus 로고    scopus 로고
    • Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: A randomized controlled trial
    • E. J. Lewis, J. B. Lewis, T. Greene et al., "Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial," American Journal of Kidney Diseases, vol. 58, no. 5, pp. 729-736, 2011.
    • (2011) American Journal of Kidney Diseases , vol.58 , Issue.5 , pp. 729-736
    • Lewis, E.J.1    Lewis, J.B.2    Greene, T.3
  • 29
    • 84863393468 scopus 로고    scopus 로고
    • Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy
    • D. K. Packham, R. Wolfe, A. T. Reutens et al., "Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy," Journal of theAmericanSociety ofNephrology, vol. 23, no. 1, pp. 123-130, 2012.
    • (2012) Journal of TheAmericanSociety OfNephrology , vol.23 , Issue.1 , pp. 123-130
    • Packham, D.K.1    Wolfe, R.2    Reutens, A.T.3
  • 30
    • 77953013434 scopus 로고    scopus 로고
    • Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy
    • M. Rossini, T. Naito, H. Yang et al., "Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy," Nephrology Dialysis Transplantation, vol. 25, no. 6, pp. 1803-1810, 2010.
    • (2010) Nephrology Dialysis Transplantation , vol.25 , Issue.6 , pp. 1803-1810
    • Rossini, M.1    Naito, T.2    Yang, H.3
  • 31
    • 84878568490 scopus 로고    scopus 로고
    • Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats
    • J. J. Cha, Y. S. Kang, Y. Y. Hyun et al., "Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats," Life Sciences, vol. 92, no. 23, pp. 1118-1124, 2013.
    • (2013) Life Sciences , vol.92 , Issue.23 , pp. 1118-1124
    • Cha, J.J.1    Kang, Y.S.2    Hyun, Y.Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.